Search

As long-term cancer survival outcomes improve, the brain has increasingly become a site of refractory and recurrent disease.

… Thursday, May 22, 2025 As long-term cancer survival outcomes improve, the brain has increasingly become a site of refractory and recurrent disease. At Memorial Sloan Kettering Cancer Center (MSK),  neurosurgeon Nelson Moss, MD , Co-Director of the  Multidisciplinary Brain Metastasis Program , and  radiation

Sloan Kettering Institute investigators are taking important steps toward being able to identify all the cell types in tumors. With this information, they can figure out how the cells work together.

… Thursday, June 28, 2018 Summary Sloan Kettering Institute investigators are laying the groundwork for research into the different cell types in found in and around tumors. The composition of malignant tumors is incredibly complex. They contain not only cancer cells but also dozens of other cell types

Charles Sawyers, Chair of Memorial Sloan Kettering’s Human Oncology and Pathogenesis Program, is widely recognized as someone who is revolutionizing the molecular treatment of cancer.

… Saturday, December 8, 2012 Summary Charles Sawyers, Chair of Memorial Sloan Kettering’s Human Oncology and Pathogenesis Program, is widely recognized as someone who is revolutionizing the molecular treatment of cancer. President Barack Obama announced on December 6 his intent to appoint Memorial Sloan

An antibody that targets a prostate cell protein shows potential for designing safer, more effective prostate cancer therapies.

… Tuesday, April 24, 2018 Summary Current prostate cancer drugs often lose their effectiveness over time. A new approach involves using an antibody to deliver toxic radioactive particles selectively to prostate cancer cells. There are many effective prostate cancer drugs, but a major challenge is that

An interdisciplinary team from Memorial Sloan Kettering Cancer Center has shown how antibiotics can disrupt the normal, healthy balance of microorganisms in the gastrointestinal tract.

… Friday, April 1, 2011 Summary An interdisciplinary team from Memorial Sloan Kettering Cancer Center has shown how antibiotics can disrupt the normal, healthy balance of microorganisms in the gastrointestinal tract. An interdisciplinary team from Memorial Sloan Kettering Cancer Center has shown that antibiotics

Our study, published recently in the Annals of Oncology, suggests that the greatest determinants of COVID-19 severity were patient features and comorbidities, such as a history of heavy smoking and chronic obstructive pulmonary disease (COPD).

… Thursday, July 16, 2020 COVID-19 was severe in patients with lung cancer, but deaths were mainly related to patient-specific features, not cancer-specific features or treatments, according to our retrospective study of 102 patients with lung cancer and COVID-19 diagnoses at Memorial Sloan Kettering Cancer

Within moments of speaking with Lucy Fleming, you notice she is always smiling. It’s a bright smile that radiates warmth. Lucy channels this positive energy as manager of the Patient Access Service at Memorial Sloan Kettering Cancer Center (MSK).

… Tuesday, June 7, 2022 Lucy with her family Lucy with her family Within moments of speaking with Lucy Fleming, you notice she is always smiling. It’s a bright smile that radiates warmth. Lucy channels this positive energy as manager of the Patient Access Service  at Memorial Sloan Kettering Cancer Center

Learn about what DNA repair looks like under a microscope.

… Friday, May 19, 2017 Summary When DNA is damaged, a cell stops dividing and recruits “lifeguard proteins” and repair proteins to get its life cycle back on track. The first microscope was invented almost 500 years ago, when two Dutch scientists placed lenses in a tube and found that they could magnify

MSK investigators report exciting results for a new molecule that can block 16 different mutated forms of the KRAS protein. In the lab, the compound was effective against many cancer cell lines and in mouse models of lung cancer and colorectal cancer.

… Wednesday, May 31, 2023 KRAS was one of the first cancer genes ever discovered, but for a long time the cancer-causing KRAS protein was considered “undruggable” with targeted therapy. That started to change in May 2021, when the Food and Drug Administration granted accelerated approval to sotorasib (

Cycle for Survival, the official rare cancer fundraising event of Memorial Sloan Kettering Cancer Center (MSK), will begin its 2024 signature team stationary-cycling events. As the founding partner of Cycle for Survival, Equinox will have its instructors leading high-energy rides across the country. 100% of the funds raised go directly to rare cancer research at MSK.

… Friday, February 2, 2024 Cycle for Survival, the official rare cancer fundraiser for Memorial Sloan Kettering Cancer Center (MSK), will kick off its annual team stationary-cycling fundraising events this weekend. Its community of people with rare cancers, survivors, caregivers, supporters, doctors, researchers